Inify Laboratories signs agreement with University Hospitals Plymouth NHS Trust to support faster prostate cancer diagnostics
South Oxfordshire, UK, 8th June 2026 - Inify Laboratories, a unique laboratory service that provides diagnostics within pathology, today announced that it has entered into an agreement with University Hospitals Plymouth NHS Trust (UHP) to launch a service evaluation. The evaluation aims to support the consistent delivery of a 7-day histopathology turnaround time and improve performance improvement against the 28-day Faster Diagnosis Standard (FDS). The partnership seeks to ensure patients with suspected prostate cancer receive timely, high -quality diagnostic results.
Across the country, cancer waiting times (CWT) remain under significant pressure, with many NHS trusts struggling to meet national targets for timely diagnosis and treatment due to high demand and constrained resources. Prostate cancer diagnostics is one area particularly affected by hugely variable reporting times. NHS targets, including the 28-day FDS, place clear emphasis on delivering timely results to patients. Delays in laboratory processing of tissue and pathology reporting can impact the entire clinical pathway, requiring additional administrative time to track results, rearrange clinics, and manage patient expectations.
The collaboration between Inify Laboratories and UHP is designed to support more consistent and predictable histopathology turnaround times, helping the Trust reliably achieve its 7-day histopathology target, and helping clinicians receive high-quality diagnostic reports within agreed timeframes. By combining digital workflows, AI-supported analysis, and streamlined laboratory processes, the service evaluation seeks to reduce variation, improve efficiency, and ultimately enhance patient experience.
"Our goal is to provide a reliable, high-quality service," says Rob Archer and Louise Keers, Laboratory Operations Managers at UHP. "By releasing laboratory capacity in one area, we can enable staff to focus on other clinical priorities and support improved turnaround times across additional indications - helping us meet national cancer targets more sustainably.''
"We're very pleased to support this service evaluation in partnership with University Hospitals Plymouth NHS Trust and Inify Laboratories," says Sunita Berry, Managing Director of the Peninsula Cancer Alliance. "Improving diagnostic timeliness is a key priority across our region, and initiatives that bring greater consistency and efficiency to the prostate cancer pathway are extremely welcome. We're excited to see the potential impact this collaboration could have for both patients and clinical teams."
"This partnership reflects what can be achieved when clinical expertise, digital innovation and service design come together," says Kate Bucknall, Managing Director UK at Inify Laboratories. "Inify delivers a dependable, end-to-end service that brings greater efficiency and sustainability to the prostate cancer pathway."
The service evaluation reflects a shared commitment between Inify Laboratories and UHP to improve cancer pathways, reduce patient anxiety associated with waiting for results, and support sustainable cancer diagnostic services for the future.
For further information, please contact Kate Bucknall, Managing Director, Inify Laboratories Ltd, kate.bucknall@inify.com, or visit https://www.inify.com
###
This information is considered to be inside information pursuant to the EU Market Abuse Regulation (MAR) and is subject to the disclosure requirements pursuant to MAR article 17 and section 5-12 the Norwegian Securities Trading Act.
This stock exchange announcement was published by Ann-Charlotte Linderoth, Inify Laboratories AB on the time and date provided.
###
The future of diagnostics
Inify Laboratories offers diagnostics through specialised laboratory services in histopathology, with a focus on streamlining patient pathways. The company performs clinical diagnostics in prostate cancer and gastroenterology, providing an integrated service that spans from early sample handling to final diagnosis. The laboratory system is scalable both in handling large volumes of patient samples and for replicating in new locations.
Quality and response times are optimised in every step - from logistics to tissue preparation and diagnosis - using a fully digital, standardised and AI -assisted workflow. The diagnosis is always performed by a pathologist and is assisted by Inify's proprietary AI, proven to have world-leading precision in clinical evaluations. The entire workflow is supported by a tailor-made system that also enables development to include additional diagnostic areas.
Inify Laboratories is an international group headquartered in Solna, Sweden, with local laboratories in Sweden and the UK. The company's share is listed on Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103 -MERK) under the ticker INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)